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Impact of operative indication and surgical
complexity on outcomes after thoracic
endovascular aortic repair at National Surgical
Quality Improvement Program Centers
Bryan A. Ehlert, MD, Christopher A. Durham, MD, Frank M. Parker, DO, William M. Bogey, MD,
Charles S. Powell, MD, and Michael C. Stoner, MD, RVT, Greenville, NC
Introduction: Thoracic endovascular aortic repair (TEVAR) devices are increasingly being utilized to treat aortic
pathologies outside of the original Food & Drug Administration (FDA) approval for nonruptured descending thoracic
aorta aneurysms (DTAs). The objective of this study was to evaluate the outcomes of patients undergoing TEVAR,
elucidating the role of surgical and pathologic variables on morbidity and mortality.
Methods: National Surgical Quality Improvement Program (NSQIP) data were reviewed for all patients undergoing
endovascular thoracic aorta repair from 2005 to 2007. The patients’ operative indication and surgical complexity were
used to divide them into study and control populations. Comorbid profiles were assessed utilizing a modified Charlson
Comorbidity Index (CCI). Thirty-day occurrences of mortality and serious adverse events (SAEs) were used as study
endpoints. Univariate and multivariate models were created using demographic and clinical variables to assess for
significant differences in endpoints (P < .05).
Results: A total of 440 patients undergoing TEVAR were identified. When evaluating patients based on operative
indication, the ruptured population had increased mortality and SAE rates compared to the nonruptured DTA
population (22.6% vs 6.2%;P < .01 and 35.5% vs 9.1%;P < .01, respectively). Further analysis by surgical complexity
revealed increased mortality and SAE rates when comparing the brachiocephalic aortic debranching population to the
noncovered left subclavian artery population (23.1% vs 6.5%; P  .02 and 30.8% vs 9.1%; P < .01, respectively).
Multivariate analysis demonstrated that operative indication was not a correlate of mortality or SAEs (odds ratio [OR], 0.95;
P  .92 and OR, 1.42; P  .39, respectively); however, brachiocephalic aortic debranching exhibited a deleterious effect
on mortality (OR, 8.75; P < .01) and SAE rate (OR, 6.67; P  .01).
Conclusion: The operative indication for a TEVAR procedure was not found to be a predictor of poor patient outcome.
Surgical complexity, specifically the need for brachiocephalic aortic debranching and aortoiliac conduit, was shown to
influence the occurrence of SAEs in a multivariate model. Comparative data, such as these, illustrate real-world outcomes
of patients undergoing TEVAR outside of the original FDA-approved indications. This information is of paramount
importance to various stakeholders, including third-party payers, the device industry, regulatory agencies, surgeons, and
their patients. ( J Vasc Surg 2011;54:1629-36.)
d
i
s
m
c
s
w
d
i
H
e
i
m
a
p
a
r
t
cThe traditional treatment for pathologies of the tho-
racic aorta is surgical repair with interposition graft via an
open thoracotomy. This treatment modality is associated
with high rates of mortality and neurologic deficits, ranging
from 8% to 9% and 7% to 16%, respectively, in previous
high-volume studies.1-3 Although the development of sur-
gical adjuncts, including distal aortic perfusion, cerebrospi-
nal fluid drainage, and epidural cooling has demonstrated
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doi:10.1016/j.jvs.2011.05.116ecreased incidence of neurologic deficits, elevated mortal-
ty rates continue to plague patients undergoing open
urgical repair.4,5
The introduction of endovascular stent grafts as a treat-
ent option for descending thoracic aortic aneurysms oc-
urred in the early 1990s.6 Initially, patient outcomes were
imilar to those seen in patients undergoing open repair
ith adjuncts.7 Other early studies with first-generation
evices revealed either no benefit in patient outcomes or
ncreased rates of endoleak and need for reintervention.8,9
owever, the phase II results for the Gore TAG thoracic
ndoprosthesis (W.L. Gore and Associates, Flagstaff, Ariz)
n 2005 demonstrated superior results in regard to patient
ortality and paraplegia compared to traditional treatments,
s well as improved aneurysm sac exclusion compared to
revious thoracic endovascular aortic repair (TEVAR) tri-
ls.10 In the 5-year follow-up to this study, aneurysm-
elated mortality and neurologic complications continued
o be significantly decreased compared to the open repair
ohort while implementation of next generation devices
mproved sac exclusion.11 These data have been replicated
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December 20111630 Ehlert et alby other graft manufacturers. Furthermore, a meta-analysis
comparing TEVAR to open surgical repair reinforced find-
ings that the TEVAR cohort had improved outcomes,
particularly related to 30-day mortality and paraplegia.12
Although the only Food & Drug Administration
(FDA)-approved instruction for use of thoracic aortic en-
dografts is for nonruptured descending thoracic aorta an-
eurysms (DTAs), endografts are increasingly being used to
treat off-label pathologies. Thoracic endograft placement
has been found to be efficacious and safe for use in the
treatment of off-label pathologies such as type B aortic
dissection, penetrating atherosclerotic ulcer, intramural he-
matoma, pseudoaneurysms, acute traumatic aortic disrup-
tion, and left subclavian artery aneurysms.13-17 A majority
of the studies investigating outcomes of patients who un-
dergo TEVAR lump them into a single population, result-
ing in a paucity of literature comparing patients with TE-
VAR outcomes based on their operative indication,
nonruptured DTA vs off-label pathology. The objective of
this study was to evaluate the outcomes of patients under-
going TEVAR for off-label pathologies utilizing the Amer-
ican College of Surgeons - National Surgical Quality Im-
provement Project (ACS-NSQIP) databases and to
elucidate the role of surgical and pathologic variables on
morbidity and mortality.
METHODS
Database. The NSQIP began as a quality improve-
ment initiative for the Veterans Affairs (VA) health system
in 1994.18 TheNSQIPwas extended into the private sector
in (1999) based on the success of the program within the
VA.19 Currently, the NSQIP is commercially available to
eligible high-volume hospitals across the United States,
with 211 different sites enrolled as of 2008.20
Surgical patients are prospectively identified and ran-
domly sampled. Medical records, operative logs, and pa-
tient interviews are used to obtain baseline clinical, demo-
graphic, perioperative, and 30-day postoperative data.
Collected data are inserted into a database using an identi-
cal methodology for the VA and private sector. Data are
gathered over the entirety of the 30-day postoperative
period, including patients that have been discharged to the
outpatient setting.
Case selection. The ACS-NSQIP databases were used
to identify all cases of TEVAR performed from 2005 to
2007, based on the primary or concurrent Current Proce-
dural Terminology (CPT) codes 33880, 33881, 33883,
and 33886. Patients were then divided into two study and
control populations, the first based on operative indication
and the second on surgical complexity. The operative indi-
cation was defined using International Classification of
Disease, 9th Revision, and Related Health Problems codes.
The study population included all patients undergoing
TEVAR for off-label pathologies, while the control popu-
lation consisted of TEVAR cases for nonruptured DTA.
The off-label pathologies identified included thoracic and
abdominal aorta dissection, aneurysm rupture, and a variety
of other conditions (see Appendix, online only). Further-ore, patients with complex anatomy were identified by
PT codes and encompassed the study population for
urgical complexity. Surgical complexity was defined as
equiring left subclavian artery (LSCA) coverage (CPT
ode 33880), visceral aortic debranching (CPT codes
5631 and 35281), or brachiocephalic aortic debranching
CPT codes 35626, 35606, 35695, 33889, or 33891).
atients with noncovered LSCA, defined as requiring nei-
her of these maneuvers, comprised the control population.
f a patient underwent coverage of the LSCA by an en-
ograft but received an adjunctive procedure via brachio-
ephalic aortic debranching, he or she was excluded from
he LSCA coverage subset and placed into the brachioce-
halic aortic debranching cohort.
Demographic and clinical variables. Basic demo-
raphic data on each population was collected, including
ge and gender. To assess the patients’ preoperative health,
modified Charlson Comorbidity Index (CCI) was calcu-
ated for each population.21 Previous studies have shown
hat adapted CCI have been similar in efficiency and prog-
osis to the original CCI.22,23 The comorbidities used to
etermine the modified CCI were chronic obstructive pul-
onary disease, esophageal varices, ascites, peripheral vas-
ular disease, cerebrovascular disease, hemiplegia, myocar-
ial infarction, congestive heart failure, end-stage renal
isease, dementia, diabetes mellitus, cancer, and age. Other
linical variables that were examined include history of
ypertension, coronary artery disease, smoking, and preop-
rative creatinine. Surgical variables were also examined
nd included the American Society of Anesthesiology
ASA) classification, operative time, number of packed red
lood cell (PRBC) units transfused intraoperatively, preop-
rative creatinine and hematocrit values, need for proximal
tent deployment, creation of an aortoiliac conduit, and
mergent nature of operation.
Outcome variables. The study endpoints were 30-day
ortality, serious adverse events (SAEs), and composite
vents. SAEs were defined, as per the ACS-NSQIP data
ictionary, as an occurrence of:
● Graft failure – mechanical failure of an extracardiac
vascular graft or prosthesis, including need for balloon
angioplasty;
● Myocardial infarction – a new transmural acute myo-
cardial infarction occurring during surgery or within
30 days following surgery as manifested by new Q-
waves on electrocardiogram;
● Cardiac arrest – the absence of cardiac rhythm or
presence of chaotic cardiac rhythm that results in loss
of consciousness requiring the initiation of any com-
ponent of basic and/or advanced cardiac life support;
● Neurologic deficit – peripheral nerve damage may
result from damage to the nerve fibers, cell body, or
myelin sheath during surgery;
● Cerebrovascular accident (CVA) – patient develops an
embolic, thrombotic, or hemorrhagic vascular acci-
dent or stroke with motor, sensory, or cognitive dys-
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Volume 54, Number 6 Ehlert et al 1631function (eg, hemiplegia, hemiparesis, aphasia, sensory
deficit, impaired memory) that persists for24 hours;
● Acute renal failure – in a patient who did not require
dialysis preoperatively, worsening of renal dysfunction
postoperatively requiring hemodialysis, ultrafiltration,
or peritoneal dialysis;
● Required return to the operating room – returns to the
operating room include all surgical procedures that
required the patient to be taken to the surgical oper-
ating room for intervention of any kind.
Myocardial infarction was determined based on new
Q-wave electrocardiogram changes, as cardiac isoenzyme
testing is not part of the routine data collection. A third
variable, composite events, was evaluated and defined as the
occurrence of either mortality or SAE.
Statistical analysis. SAS software, version 9.2, of the
SAS System for Windows (SAS Institute, Cary, NC) was
used to generate the analysis. The 2, Wilcoxon, and t test
were used to perform univariate analysis comparing popu-
lation demographics, clinical variables, and study end-
points. Multivariate logistic regression analysis was also
used to explore independent associations with clinical co-
variates. Pertinent study variables and clinical variables
found to be significant on univariate analysis for the primary
outcomes were included in the multivariate model. Fur-
thermore, comorbid conditions were analyzed in the mul-
tivariate model by using the CCI, where an elevated CCI
was defined as being greater than 4. Patients in the “rup-
tured aneurysm” cohort were excluded before performing
multivariate analyses secondary to the inherent increased
morbidity and mortality rates associated with these pa-
tients. Combining such a heterogeneous group of patients
would have introduced an inherent bias to the results. All
remaining clinical variables incorporated into the model
were defined as being elevated or decreased by using the
mean and one SD of the population as a whole. Odds ratios
(ORs) and 95% confidence intervals were calculated using
the variables identified as above. Throughout the article,
data are presented as mean SD or median interquartile
range with a P value of  .05 being considered statistically
significant. This study was approved by the Institutional
Review Board of East Carolina University.
RESULTS
Patient population. Using the CPT codes for TE-
VAR listed above, a total of 440 patients were identified
from 183 centers during the study period. Two hundred
seventy-five patients underwent TEVAR for nonruptured
DTA (62.5%), while TEVAR was performed in 165 pa-
tients for off-label pathologies, including thoracic aorta
dissection (n  106; 24.1%), aneurysm rupture (n  31;
7.1%), and other conditions (n 28; 6.4%). Two hundred
eighty-seven patients had a noncovered LSCA (65.2%),
131 required LSCA coverage (29.8%), nine had visceral
aortic debranching (2.0%), and 14 underwent brachioce-
phalic aortic debranching (3.2%). The remaining demo- traphic and clinical characteristics of the patient population
re described in Table I.
Operative indication. The patients were initially
tratified by operative indication and univariate analysis was
onducted to compare the study and control populations
Table II). The control population was comprised of all
atients undergoing TEVAR for nonruptured DTA. The
horacic aorta dissection and “other” populations were
ounger than the control population (P  .01), whereas
he aneurysm rupture population was predominantly male
P  .04). Comparisons of the comorbid profiles of the
opulations found the thoracic aorta dissection and
other” populations to have decreased CCIs (P  .01)
hile the aneurysm rupture population was well matched.
SA classifications were elevated in the thoracic aorta dis-
ection and aneurysm rupture populations (P .01). Anal-
sis of variables associated with the operation showed that
he populations were well matched in regard to operative
ime and preoperative creatinine; however, the aneurysm
upture population required an increased amount of trans-
used PRBC units and had a decreased preoperative hemat-
crit compared to the control group (P  .01). The tho-
acic aorta dissection population also had a decreased
reoperative hematocrit (P  .01). The study group had a
ignificantly increased need for emergent TEVAR com-
ared to the control group (P .01). The study populations
ere comparable to the control population regarding the
eed for proximal stent deployment. When comparing aor-
able I. Characteristics of patients undergoing TEVAR
rom 2005 to 2007
All (n  440)
emographic
Age (years) 67.5  14.5
Male 60.0%
linical
Charlson Comorbidity Index 3  2
ASA classification 3  1
Hypertension 87.5%
Chronic obstructive pulmonary disease 20.5%
Coronary artery disease 33.6%
Diabetes 10.7%
Smoking history 32.3%
Dialysis 4.6%
Emergent 15.0%
Preoperative creatinine (mg/dL) 1.38  1.32
ndication
Nonruptured DTA 62.5%
Dissection 24.1%
Ruptured 7.1%
Other 6.4%
urgical complexity
Noncovered LSCA 65.2%
LSCA coverage 29.8%
Visceral aortic debranching 2.0%
Brachiocephalic aortic debranching 3.2%
SA, American Society of Anesthesiologists; DTA, descending thoracic
orta aneurysm; LSCA, left subclavian artery; TEVAR, thoracic endovascu-
ar aortic repair.oiliac conduit creation, the thoracic aorta dissection cohort
t
w
(
f
.
r
g
L
a
.
v
p
d
f
T
r
p
p
c
b
t
JOURNAL OF VASCULAR SURGERY
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(P .05). The thoracic aorta dissection and aneurysm rupture
populations were well matched to the control group regard-
ing surgical complexity; conversely, the “other” population
was more likely to require brachiocephalic aortic debranching
(P  .01). When evaluating patient outcomes, the only sig-
nificant differences occurred between the ruptured aneurysm
and control populations, where the ruptured aneurysm pop-
ulation had increased mortality, SAEs, and composite rates
(P .01). One patient undergoing TEVAR for a nonruptured
DTA with a noncovered LSCA developed acute renal failure
postoperatively. Due to the small incidence of this complication,
it was not included in the multivariate regressionmodels.
Surgical complexity. The patients were then stratified
by surgical complexity, and univariate analysis again was
performed to evaluate the study and control populations
(Table III). The LSCA coverage population was older than
the control group (P .03); however, all of the remaining
demographic, comorbid, and operative variables were com-
parable between the study and control populations. The
visceral and brachiocephalic aortic debranching popula-
tions had increased operative times (P  .01) and the
Table II. Characteristics and outcomes of patients underg
indication
All
(n  440)
Nonr
(
Population
Age (years) 67.5  14.5 69
Male 60.0%
Charlson Comorbidity Index 3  2
ASA classification 3  1
Case
Operative time (minutes) 178.0  112.2 180
PRBC transfusion (units) 0.93  2.04 0
Pre-op creatinine (mg/dL) 1.38  1.32 1
Pre-op hematocrit (%) 36.2  6.28 37
Emergent 15.0%
Proximal grafts deployed 20.0%
Aortoiliac conduit 7.0%
Surgical complexity
Noncovered LSCA 65.2%
LSCA coverage 29.8%
Visceral aortic debranching 2.0%
Brachiocephalic aortic debranching 3.2%
Outcome
Mortality 7.1%
SAE 11.4%
Cardiac arrest 3.6%
Myocardial infarction 0.5%
Graft failure 1.4%
Neurologic deficit 0.5%
CVA 6.1%
Return to operating room 10.9%
Composite 13.4%
ASA, American Society of Anesthesiologists; CVA, cardiovascular accident;
packed red blood cells; SAE, serious adverse events; TEVAR, thoracic endo
a P  .01 vs nonruptured DTA.
b P  .05 vs nonruptured DTA.visceral aortic debranching cohort had increased PRBC Sransfusion requirements (P .01). Preoperative creatinine
as increased in the visceral aortic debranching population
P  .05). Brachiocephalic aortic debranching was per-
ormedmore frequently for miscellaneous pathologies (P
01), while the LSCA coverage and visceral aortic deb-
anching populations were representative of the control
roup. Proximal stent deployment was required less in the
SCA coverage cohort (P  .01), whereas incidence of
ortoiliac conduit creation was increased in this subset (P
01). Aortoiliac conduits were also more frequent in the
isceral aortic debranching population (P  .01). In com-
aring patient outcomes, the LSCA coverage population
id not have an increased overall SAE rate; however, it was
ound to have an increased occurrence of CVA (P  .02).
he LSCA coverage cohort had a decreased incidence of
eturn to the operating room compared to the control
opulation (P  .02). The visceral aortic debranching
opulation had an increased incidence of neurologic defi-
its (P  .01), whereas the brachiocephalic aortic de-
ranching population had a more profound effect on pa-
ient outcomes with increased rates of mortality (P  .02),
TEVAR from 2005 to 2007, stratified by operative
Operative indication
ed DTA
75)
Dissection
(n  106)
Rupture
(n  31)
Other
(n  28)
12.4 62.3  16.0a 74.1  12.0 56.8  18.8a
% 57.6% 45.2%b 50.0%
1 2  3a 4  2 2.5  3a
1 4  1a 4  0a 3  1
119.3 166.0  81.7 167.6  102.2 211.1  144.4
2.1 0.7  1.5 2.2  3.2a 1.0  1.4
1.2 1.5  1.6 1.6  1.6 1.1  0.8
6.1 33.9  5.5a 33.2  7.5a 36.1  6.4
% 26.4%a 74.2%a 21.4%a
% 19.8% 22.6% 28.6%
% 2.8%b 16.1% 0.0%
% 63.2% 64.5% 53.6%
% 35.9% 32.3% 28.6%
% 0.0% 0.0% 3.6%
% 0.9% 3.2% 17.9%
% 4.7% 22.6%a 7.1%
% 10.4% 35.5%a 10.7%
% 4.7% 6.5% 7.1%
% 0.0% 3.2% 0.0%
% 1.9% 0.0% 0.0%
% 0.0% 0.0% 0.0%
% 4.7% 25.8%a 3.6%
% 14.2% 6.5% 14.3%
% 11.3% 45.2%a 10.7%
descending thoracic aorta aneurysm; LSCA, left subclavian artery; PRBC,
ar aneurysm repair.oing
uptur
n  2
.9 
63.6
4 
3 
.4 
.9 
.3 
.5 
3.3
20.0
8.4
69.8
27.6
2.9
2.6
6.2
9.1
2.6
0.4
1.5
0.7
4.7
9.8
10.9
DTA,
vasculAE (P  .01), and composite events (P  .03).
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models were constructed to evaluate for possible covariates asso-
ciatedwith adverse patient outcomes, includingoperative indica-
tion and surgical complexity (Tables IV and V). Operative indi-
cation was not found to have a deleterious effect on mortality
(OR, 1.35; P  .56). Among the surgical complexity popula-
tions, the brachiocephalic aortic debranching cohort was found
to be a correlate for mortality (OR, 8.75; P  .01). Other
variables foundtobecorrelatesofmortalitywereanelevatedASA
(OR, 3.30; P .01), increased PRBC transfusion requirement
(OR, 4.94; P .02), and creation of an aortoiliac conduit (OR,
10.3;P .01).Whenevaluating forcovariatesofSAEs,operative
indication was not predictive of SAEs (OR, 0.85; P  .68);
however, brachiocephalic aortic debranchingwas the lone surgi-
cal complexity cohort found to be a correlate for SAEs (OR,
6.67; P  .01). Creation of an aortoiliac conduit was the only
other covariate associated with an elevated SAE rate (OR, 6.21;
P .01).
DISCUSSION
Despite lacking FDA approval, thoracic aortic en-
dografts continue to be used to treat a wide range of
Table III. Characteristics and outcomes of patients under
complexity
All
(n  440)
Noncovered LS
(n  287)
Population
Age (years) 67.5  14.5 68.7  14.
Male 60.0% 62.1%
Charlson Comorbidity Index 3  2 3  2
ASA classification 3  1 3  1
Case
Operative time (minutes) 178.0  112.2 167.4  103
PRBC transfusion (units) 0.93  2.04 0.77  1.6
Pre-op creatinine (mg/dL) 1.38  1.32 1.31  1.1
Pre-op hematocrit (%) 36.2  6.28 36.1  6.0
Emergent 15.0% 14.7%
Proximal grafts deployed 20.0% 25.7%
Aortoiliac conduit 7.0% 8.4%
Indication
Nonruptured DTA 62.5% 64.8%
Dissection 24.1% 23.5%
Rupture 7.1% 6.8%
Other 6.4% 4.9%
Outcome
Mortality 7.1% 6.5%
SAE 11.4% 9.1%
Cardiac arrest 3.6% 3.9%
Myocardial infarction 0.5% 0.3%
Graft failure 1.4% 1.6%
Neurologic deficit 0.5% 0.3%
CVA 6.1% 3.9%
Return to operating room 10.9% 13.4%
Composite 13.4% 11.7%
ASA, American Society of Anesthesiologists; CVA, cardiovascular accident;
packed red blood cells; SAE, serious adverse events; TEVAR, thoracic endo
a P  .01 vs simple.
b P  .05 vs simple.pathologies, including those that require aortic debranch- tng secondary to surgical complexity. A recent study inves-
igating patient outcomes related to operative indication
ound that patients undergoing TEVAR for off-label pa-
hologies experienced increased rates of mortality and spi-
al cord ischemia (SCI).24 These findings suggest that the
se of TEVAR for off-label pathologies provides equivalent
ortality and SAE rates as when performed for nonrup-
ured DTA. Although the aneurysm rupture cohort in this
tudy had significant increases in all adverse patient out-
omes, it also was associated with increased CCI, ASA
lassification, PRBC transfusion requirement, and rate of
mergent operation, illustrating the grave prognosis of
hese patients.25 Due to the inherent bias in this patient
opulation, they were excluded before multivariate analy-
es. When the study and control populations were analyzed
n the multivariate model, operative indication was not
ound to be a correlate of 30-day mortality or SAEs.
Emergent nature of the procedure did not correlate
ith increasedmortality or SAE rates. Previous studies have
eported similar findings as well.24,26 The lack of signifi-
ance for those undergoing emergent procedures may be
xplained by the finding that the patient populations with
g TEVAR from 2005 to 2007, stratified by surgical
Surgical complexity
LSCA coverage
(n  131)
Visceral aortic
debranching (n  9)
Brachiocephalic aortic
debranching (n  14)
63.9  14.2a 72.3  12.1 66.3  13.9
54.1% 57.1% 69.2%
3  2 4  2 4  2
3  1 4  1 4  1
169.3  99.5 433.1  88.1a 329.0  141.3a
1.04  2.62 4.00  2.83a 1.54  1.66
1.53  1.67 2.23  2.74b 1.36  1.06
36.5  7.19 35.8  3.33 38.4  4.35
17.1% 0.0% 15.4%
0.0%a 28.6% 15.4%
2.3%a 42.9%a 0.0%
55.9% 85.7% 46.2%
29.7% 0.0% 7.7%
8.1% 0.0% 7.7%
6.3% 14.3% 38.5%a
6.3% 0.0% 23.1%b
13.5% 14.3% 30.8%a
1.8% 0.0% 15.4%b
0.0% 0.0% 7.7%a
0.9% 0.0% 0.0%
0.0% 14.3%b 0.0%
9.9%b 0.0% 15.4%b
5.4%b 14.3% 0.0%
14.4% 14.3% 30.8%b
descending thoracic aorta aneurysm; LSCA, left subclavian artery; PRBC,
ar aneurysm repair.goin
CA
5
.1
6
3
7
DTA,
vasculhe highest mortality and SAE rates, aneurysm rupture, and
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in need for emergent repair. The aneurysm rupture popu-
lation by in large required emergent intervention, as ex-
pected, whereas a vast majority of the brachiocephalic
Table IV. Multivariate model for correlates of mortality
in nonruptured patients undergoing TEVAR from 2005
to 2007
Odds
ratio
95%
Confidence
interval
P
value
Descending thoracic aorta
aneurysm
1.35 0.49-3.77 .56
LSCA coverage 1.28 0.45-3.63 .64
Brachiocephalic aortic
debranching
8.75 1.69-45.2 .01a
Visceral aortic debranching 0.16 0.01-2.62 .20
Elevated ASA (3) 3.30 1.26-8.65 .01a
End-stage renal disease 1.74 0.83-3.66 .15
Increased CCI (4) 1.93 0.74-5.02 .18
Increased operative time
(290 minutes)
0.77 0.20-2.91 .70
Increased PRBC
transfusion (3 units)
4.94 1.24-19.68 .02b
Aortoiliac conduit 10.3 2.67-39.64 .01a
ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity
Index; LSCA, left subclavian artery; PRBC, packed red blood cells; TEVAR,
thoracic endovascular aneurysm repair.
aP  .01.
bP  .05.
Table V. Multivariate model for correlates of SAEs in
nonruptured patients undergoing TEVAR from 2005 to
2007
Odds
ratio
95%
Confidence
interval
P
value
Descending thoracic aorta
aneurysm
0.85 0.38-1.87 .68
LSCA coverage 2.01 0.90-4.46 .09
Brachiocephalic aortic
debranching
6.67 1.55-28.64 .01a
Visceral aortic debranching 1.27 0.16-9.84 .82
Elevated ASA (3) 1.75 0.83-3.69 .14
Proximal extensions deployed 2.19 0.98-4.90 .06
Extended operative time
(290 minutes)
0.85 0.28-2.61 .78
Increased CCI (4) 1.59 0.70-3.60 .78
CVA 1.66 0.66-4.13 .28
Hypertension 5.52 0.69-43.98 .11
Diabetes mellitus 0.15 0.02-1.16 .07
Increased PRBC transfusion
(3 units)
3.04 0.92-10.08 .07
Aortoiliac conduit 6.21 1.79-21.50 .01b
ASA, American Society of Anesthesiologists; CCI, Charlson Comorbidity
Index; CVA, cardiovascular accident; LSCA, left subclavian artery; PRBC,
packed red blood cells; SAEs, serious adverse events; TEVAR, thoracic
endovascular aneurysm repair.
aP  .01.
bP  .05.aortic debranching cohort underwent elective procedures, fikely due to the increased amount of planning necessary for
hese complex cases. The distinct differences between these
wo populations likely resulted in emergent nature of TE-
AR not being identified as a correlate of mortality or
AEs.
The operative factors we found to significantly influ-
nce mortality and SAE rates were brachiocephalic aortic
ebranching and aortoiliac conduit creation. Univariate
nalysis demonstrated that coverage of the LSCA and vis-
eral aortic debranching had a significantly increased occur-
ence of stroke and neurologic deficit, respectively, while
rachiocephalic aortic debranching significantly impacted
ach of the adverse patient outcomes. Initially, studies
uggested that intentional coverage of the LSCA could be
erformed without resulting in functional deficit or left
pper extremity malperfusion.27,28 However, more recent
nvestigations have revealed that coverage of the LSCA
ithout revascularization is a correlate of SCI and those
atients at risk for the development of SCI or stroke may
enefit from prophylactic adjunctive procedures to restore
ow to the LSCA.29,30 The data from this study support
hese findings that patients undergoing coverage of the
SCA are at an increased risk of adverse neurologic events.
Patients undergoing concurrent brachiocephalic aortic
ebranching had increased mortality, SAEs, and composite
ates. Although they were well matched demographically
nd by comorbidities compared to the control group, these
atients were subjected to prolonged operative times (av-
raging over 5 hours). Furthermore, a higher percentage of
his population underwent TEVAR for pathologies other
han nonruptured DTA, thoracic aorta dissection or aneu-
ysm rupture, possibly indicating higher degrees of case
omplexity. The cumulative effects of these factors may
xplain the drastic increase in adverse outcomes observed in
his population of patients, as previous studies evaluating
arotid-subclavian bypass do not support such high mor-
idity and mortality rates.31 These findings are representa-
ive of other studies investigating TEVAR with concurrent
ortic debranching, demonstrating comparable neurologic
eficit rates to open repair (4%-12%).32-34 In studies in
hich patients are more likely to undergo a staged proce-
ure, some authors have demonstrated that mortality and
eurologic deficits approach those of TEVAR alone.35
onflicting data are found when TEVAR with aortic de-
ranching is compared to open surgical repair. Some evi-
ence suggests that the two populations have equivalent
ortality and neurologic deficit rates, with the hybrid
peration cohort having a significantly increased reinter-
ention rate.36 Conversely, when the hybrid operation
opulation includes a vast majority of patients undergoing
staged procedure, some evidence suggests patients have
mproved mortality and neurologic deficit rates compared
o the open surgical repair population.37 When discussing
atient outcomes after aortic debranching, it is important
o recognize the selection bias associated with these proce-
ures, as they are predominantly used in patients with
rofound comorbidities and considered to be unsuitable
or other treatment modalities.
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certain inherent weaknesses in this study. First, the data-
bases lack complete preoperative history, focusing mainly
on cardiopulmonary comorbidities. The absence of an ad-
equate history is pertinent, as others have demonstrated a
correlation between previous aortic surgery and adverse
outcomes in patients undergoing TEVAR.30 Furthermore,
due to the paucity of patient history, details related to the
specific indication for operative repair are absent, such as
aneurysm size and expansion, progression of dissection,
uncontrolled pain, and end-organ ischemia. Next, ACS-
NSQIP only records 30-day outcomes, preventing ade-
quate patient follow-up. As such, it does not allow for the
long-term surveillance of sac exclusion, endoleak, or graft
migration. The absence of a reliable indicator of postoper-
ative paraplegia or SCI illustrates another weakness, as the
occurrence of this dreaded complication negatively impacts
a patient’s quality of life after thoracic aorta repair. The lack
of a consistent definition for paraplegia or SCI may repre-
sent the low incidence of reported nonstroke neurologic
deficits, where patients with postoperative paraplegia or
SCI may have been mistakenly documented to have suf-
fered a CVA, possibly explaining the increased incidence of
CVA in this population compared to previously reported
rates.38 Other postoperative complications pertinent to
endovascular aortic repair absent from this particular
database are access complications, such as hematomas or
pseudoaneurysms, distal embolization, visceral ischemia,
and acute lower extremity ischemia. The exclusion of
these complications prevents a complete analysis of pa-
tient outcomes.
Despite the shortcomings of the ACS-NSQIP, it allows
for a generalized representation of patient outcomes after
TEVAR, circumventing the biases of results produced from
specialized aortic surgery centers. Trained reviewers from
each individual center are responsible for the collection of
patient data and outcomes, as opposed to nonclinician
chart extractors. The data are then audited and adjudicated
by a third party. This validated method of data collection
allows ACS-NSQIP to be more reliable than other contem-
porary databases. Furthermore, the use of a nationwide
database also permits for the compilation of a larger patient
series over a shorter time period for a disease process that
has historically had a low prevalence. The data presented
herein represent the “real-world” experience with a re-
cently approved technology, and demonstrate areas of di-
vergence from the initial prospective clinical trials.
CONCLUSIONS
In an era where aortic endografts are increasingly being
deployed in patients for off-label pathologies, the indica-
tion for TEVAR procedure was not found to be a predictor
of poor patient outcome. Surgical complexity, specifically
need for brachiocephalic aortic debranching and aortoiliac
conduit, was shown to influence the occurrence of SAE in a
multivariate model. Comparative data, such as these, illus-
trate “real-world” outcomes of patients undergoing TEVAR
outside of the original FDA-approved indications. This
1nformation is of paramount importance to various stake-
olders, including third-party payers, the device industry,
egulatory agencies, surgeons, and their patients.
The authors would like to acknowledge Dr Shukri F.
huri. Dr Khuri’s leadership and passion made the NSQIP
ossible and will continue to help countless surgical pa-
ients. We are grateful for his assistance and collaboration
n this article.
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Volume 54, Number 6 Ehlert et al 1636.e1Appendix, online only. List of operative indications and
their occurrences comprising the “other” cohort of
patients undergoing TEVAR between 2005 and 2007
Operative indication Occurrences
Acute bacterial endocarditis 1
Subclavian artery aneurysm 2
Coarctation of aorta 1
End-stage renal disease 1
Thoracic aorta injury 3
Mechanical complication of vascular device
implant/graft
15
Mitral valve insufficiency 1
Other complication due to vascular device
implant/graft
1
Rheumatic aortic stenosis 1
Subendocardial infarction 1
Takayasu’s syndrome 1
